Advanced Viral Research Corp.

Jun 06, 04
14:01 ET	ADVR Presented Results of its AVR118 Phase 1/2 Clinical Program at ASCO
May 10, 04
07:31 ET	ADVR Receives Second $3 Million Installment of Funding
Apr 20, 04
07:20 ET	Advanced Viral Research Corp. Announces the Resignation of Its Chief Financial Officer
Apr 08, 04
07:31 ET	ADVR Appoints Dr. Carol Epstein as Acting Medical Director
Mar 19, 04
07:30 ET	ADVR Abstract Selected for Presentation at the American Society of Clinical Oncology's (ASCO) 40th Annual Meeting
Feb 25, 04
08:14 ET	ADVR Granted a United States Patent for the Treatment of AIDS
Feb 20, 04
08:20 ET	ADVR Presented Preclinical Data at the 1st ISC International Conference on Cancer Therapeutics in Florence
Feb 12, 04
07:35 ET	ADVR Appoints Biotechnology Veteran Elma S. Hawkins As New Chief Executive Officer
Feb 04, 04
07:31 ET	ADVR Secures $12 Million Financing
Jan 27, 04
07:34 ET	ADVR to present at 1st ISC International Conference on Cancer Therapeutics - Molecular Targets, Pharmacology and Clinical Applications to be held in Florence, Italy
Jan 08, 04
07:32 ET	ADVR Granted U.S. Patent for Treatment of Human Papillomavirus Infections
Dec 11, 03
17:58 ET	ADVR Names Elma S. Hawkins to Board of Directors
Dec 09, 03
17:58 ET	AVR118 Suppresses Progression of Disease in Animal Model of Multiple Sclerosis Developed at The Weizmann Institute of Science
Dec 03, 03
13:37 ET	ADVR Reports AVR118 Inhibits Inflammatory Arthritis in Animal Model and in Rheumatoid Arthritis Patients in Human Clinical Trial
Nov 20, 03
09:22 ET	ADVR's AVR118 Granted a Patent in China for the Treatment of AIDS
Nov 18, 03
07:58 ET	Advanced Viral Research Corp. Announces Retention of James T. D'Olimpio, MD As 'Spokesperson at Large'
Nov 10, 03
08:21 ET	ADVR Reports Positive Preliminary Results of AVR118 Clinical Trial in AIDS Patients Suffering from Body Wasting (Cachexia)
Aug 28, 03
08:02 ET	ADVR Announces Search for New CEO and Appointment of Interim CEO
May 16, 03
11:23 ET	ADVR Completes Private Placement Financing Transactions
Apr 11, 03
08:35 ET	ADVR CEO Hirschman Comments on SARS on ABC World News Tonight
Mar 24, 03
07:30 ET	ADVR Granted Therapeutic Composition Patent For Product R; U.S. Patent Awarded for Chemical Structure of Novel Peptide Nucleic Acid
Mar 18, 03
07:30 ET	ADVR Begins Planning for Late Stage Phase II AIDS Clinical Trial In Israel
Feb 25, 03
18:05 ET	ADVR Pursuing Options in NY Litigation; Continues to Press Florida Lawsuit
Jan 09, 03
07:53 ET	ADVR Completes Private Placement Financing Transaction
Dec 17, 02
14:55 ET	ADVR Files Stock Manipulation Suit in Florida
Dec 12, 02
08:38 ET	Potential Use of ADVR's Product R to Treat AIDS Is Focus of A&U Magazine Article
Nov 14, 02
08:03 ET	ADVR Begins Product R Israeli Clinical Trials; Quintiles Retained to Monitor/Audit Trials, Selikoff Center to Conduct Trials
Nov 08, 02
07:46 ET	ADVR Announces Staff Reduction to Conserve Capital to Focus on Israeli Clinical Trials; Intent to Sell Bahamas Plant; Board Resignations
Oct 11, 02
07:54 ET	ADVR's Product R Reverses Cancerous Properties of Human Promyelocytic Leukemia Cells in Laboratory Cultures
Sep 25, 02
07:44 ET	Dr. Richard S. Kent Joins ADVR Board of Directors
Sep 18, 02
07:35 ET	Dr. Sidney Pestka Joins ADVR Scientific Advisory Board
Sep 10, 02
09:35 ET	ADVR Announces Completion of $3 Million Financing; Funds Enable Israeli Clinical Trials of Product R to Move Forward
Aug 20, 02
10:31 ET	ADVR's Product R Subject of Published Study on Clinical Trial For Treatment of HIV/AIDS
Jul 30, 02
17:14 ET	Paul R. Bishop Joins ADVR Board of Directors
Jul 16, 02
17:13 ET	ADVR Announces $1.5 Million Investment By Member of Board and Member of Business Advisory Board
Jun 18, 02
17:12 ET	ADVR's Product R Approved in Israel for Phase I Study In Patients with Solid Tumors
Jun 12, 02
17:11 ET	ADVR's Product R Approved in Israel for Phase I Study in Leukemia and Lymphoma Patients
Jun 10, 02
17:10 ET	Roy S. Walzer Joins Board of Directors of Advanced Viral Research Corp.
Jun 06, 02
17:09 ET	ADVR's Product R Approved in Israel for Phase I/II Study In Patients Needing Salvage Therapy For AIDS
May 23, 02
17:08 ET	ADVR Names Mayr Communications to Handle Public/Investor Relations; Firm Brings Extensive Pharmaceutical Industry Experience
May 02, 02
17:06 ET	ADVR Names Eli Wilner Chairman of the Board
Apr 23, 02
17:05 ET	ADVR's Dr. Hirschman Describes Large Potential Therapeutic Categories for Product R
Apr 16, 02
17:03 ET	ADVR Is Assigned Ownership of Two U.S. Patents in Settlement of Litigation
Apr 12, 02
17:02 ET	ADVR Begins Phase 2 of IND for Topical Treatment Of Genital Warts With Product R
Mar 20, 02
17:01 ET	ADVR's Product R Granted Patent for Topical Use In Treatment of Skin Diseases, Eye Afflictions
Mar 15, 02
16:58 ET	Dr. Howard Young - Leading Immunologist - Joins the Scientific Advisory Board Of Advanced Viral Research Corp.
Mar 11, 02
16:15 ET	Advanced Viral Research Corp. Submits Product R Topical Phase 1 Results to FDA
Jan 24, 02
16:56 ET	Advanced Viral Research Corp. Forms Scientific Advisory Board with Leaders in Oncology, Hematology, Women's Health Care